New Delhi, March 20 -- Global pharmaceutical company Eli Lilly and Company (India) has introduced Mounjaro (tirzepatide) in India, a breakthrough drug for the treatment of Type 2 diabetes and obesity.

Approved by the Central Drugs Standard Control Organization (CDSCO), Mounjaro is available in single-dose vials, with pricing set at Rs3,500 for a 2.5 mg vial and Rs4,375 for a 5 mg vial, leading to a monthly cost of Rs14,000-Rs17,500, depending on dosage.

Mounjaro, the company claimed is the first drug to target both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, offering a new approach to metabolic health management.

It is prescribed as an adjunct to diet and exercise for chronic weight...